Table 4.
Effective dose and risk as multiple of average panoramic images, days of natural background dose in Sweden and risk of cancer
| Unit/protocol | Effective dose (µSv) | Dose as multiple of average panoramic radiographa | Days of per capita natural background (2.08 µSv per day) | Excess cases of fatal cancer in 1 million peopleb |
| Veraviewepocs 3De®/upper jaw | 21 | 1.9 | 10 | 1.2 |
| Veraviewepocs 3De/lower jaw | 22 | 2.0 | 11 | 1.2 |
| ProMax® 3D/upper jaw | 10 | 0.9 | 5 | 0.6 |
| NewTom VGi®/TMJ, NR (12 × 8) | 56 | 5.1 | 27 | 3.9 |
| NewTom VGi/TMJ, NR (8 × 8) | 45 | 4.1 | 22 | 2.5 |
| NewTom VGi/TMJ, HR (8 × 8) | 129 | 11.7 | 62 | 7.1 |
| Veraviewepocs 3De/panorama | 11 | 1.0 | 5 | 0.6 |
| ProMax 3D/panorama | 8 | 0.7 | 4 | 0.4 |
| ProMax/panorama | 14 | 1.3 | 7 | 0.8 |
Veraviewepocs 3De units are manufactured by J Morita MFG Corp., Kyoto, Japan; NewTom VGi by Quantitative Radiology, Verona, Italy; and Promax 3D and Promax by Planmeca, Helsinki, Finland.
HR, high resolution; NR, normal resolution; TMJ, temporomandibular joint.
a
Average of three units: ProMax, ProMax 3D, Veraviewepocs 3De (11 µSv).
b
Based on the same study—calculated by using a risk coefficient of 5.5 × 10−2 Sv−1.